Roche pharma India marked its foray into the opthalmology space by launching VABYSMO"(faricimab)for the treatment of neovascular or wet age related macular degeneration (nAMD)and diabetic macular edema(DME).Neovascular AMD and DME are leading causes of vision loss worldwide."Vabysmo"is the first and only dual-pathway-inhibitor that uniquely targets and inhibits two disease pathways linked to a number of vision threatening retinal conditions.Vabysmo is a single molecule designed to provide the benefits of two medicines in one.
"VABYSMO" has the potential to transform the existing standard of Care (SoC) as the burden associated with currently available treatment options for nAMD & DME such as frequent eye injections (typically required every one to two months)and physician visits can lead to under treatment and less than optimal vision outcomes.
Commenting on the launch,Mr.V.Simpson Emmanuel,CEO & Managing Director,Roche Pharma India,"We believe more should be done to meet the needs of people living with retinal conditions & to preserve sight.While there is strong awareness and action for cataract and other frontal eye-disorders,retinal conditions are often diagnosed late or neglected leading to vision loss.The Launch of "VABYSMO" marks our entry into the opthalmology space in India,underscoring our commitment to bring the best-in-class innovations to the country.With fewer eye injections over time,while also improving and maintaining vision & anatomy,"VABYSMO" offers a more convenient & effective treatment schedule for patients,their caregivers and healthcare systems".
Dr.Chaitra Jayadev,Head of Vitreoretina Services at Narayana Nethralaya Eye Institute,Said, "As retina specialists, we see this as a game changer in our field,offering new hope and possibilities for our patients battling these complex retinal diseases'.
"VABYSMO" (faricimab) was first approved by the USFDA in January,2022.It is today available in across 90+countries and more than 2 million doses have been administered till date".
It was said during the discussions, that Diabetes is one of the triggering factors for Retinal Disorders.
No comments:
Post a Comment